Pharvaris (NASDAQ:PHVS) Director Robert Glassman Sells 10,000 Shares

Pharvaris N.V. (NASDAQ:PHVS) Director Robert Glassman sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $29.82, for a total value of $298,200.00. Following the sale, the director directly owned 10,500 shares of the company’s stock, valued at $313,110. This represents a 48.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Pharvaris Stock Performance

Shares of PHVS stock opened at $28.95 on Wednesday. Pharvaris N.V. has a 52-week low of $15.46 and a 52-week high of $33.33. The firm has a market capitalization of $1.89 billion, a P/E ratio of -9.10 and a beta of -2.34. The stock has a 50 day moving average price of $28.26 and a 200 day moving average price of $26.68.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. As a group, sell-side analysts forecast that Pharvaris N.V. will post -3.25 EPS for the current year.

Institutional Investors Weigh In On Pharvaris

A number of institutional investors and hedge funds have recently bought and sold shares of PHVS. Wellington Management Group LLP bought a new stake in Pharvaris during the 3rd quarter valued at $43,282,000. Paradigm Biocapital Advisors LP raised its position in Pharvaris by 72.7% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock valued at $45,796,000 after purchasing an additional 772,583 shares in the last quarter. Balyasny Asset Management L.P. purchased a new position in shares of Pharvaris in the 3rd quarter valued at $15,613,000. Commodore Capital LP increased its holdings in shares of Pharvaris by 26.5% in the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after acquiring an additional 507,043 shares during the period. Finally, General Atlantic L.P. increased its holdings in shares of Pharvaris by 6.6% in the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after acquiring an additional 500,000 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Wedbush raised their price target on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 7th. Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Wolfe Research started coverage on Pharvaris in a research report on Thursday, April 9th. They set an “outperform” rating and a $42.00 target price for the company. Finally, Wall Street Zen raised Pharvaris from a “strong sell” rating to a “sell” rating in a research report on Saturday. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Pharvaris presently has an average rating of “Moderate Buy” and a consensus price target of $49.18.

Pharvaris News Summary

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: HC Wainwright raised its earnings estimates for Pharvaris across multiple quarters and fiscal years, including higher forecasts for FY2026 through FY2030, and maintained a Buy rating with a $60 price target.
• Neutral Sentiment: Pharvaris recently reported a smaller-than-expected quarterly loss, with EPS of ($0.70) versus the consensus estimate of ($0.82), which may support sentiment but does not change the company’s near-term loss profile.
• Negative Sentiment: Insider selling by Director Robert Glassman and insider Wim Souverijns, both of whom sold 10,000 shares, may temper enthusiasm slightly because it can be viewed as reduced insider confidence. SEC filing for Robert Glassman sale SEC filing for Wim Souverijns sale

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.